国发股份因计提商誉减值被问询，业绩承压与行业环境变化成主因

Company Dynamics - Beihai Guofa Chuan Mountain Biological Co., Ltd. (stock code: 600538.SH) has attracted attention from the Shanghai Stock Exchange due to significant goodwill impairment provisions for its judicial appraisal technology subsidiary over the past three years [1] - The company expects to achieve approximately 330 million yuan in revenue for the fiscal year 2025, with a net loss attributable to shareholders of about 85 million yuan, and a net loss of approximately 85.5 million yuan after excluding non-recurring gains and losses [1] Performance Pressure - The performance pressure is directly related to a past acquisition; in 2020, Guofa acquired 99.9779% of Guangzhou Gaosheng Biotechnology Co., Ltd. for 355.6932 million yuan, entering the molecular diagnostics and judicial appraisal service sector [2] - Since 2023, Gaosheng's performance has consistently fallen short of expectations, leading to three consecutive years of goodwill impairment provisions, with 55 million yuan and 60 million yuan recorded for 2023 and 2024 respectively, and an expected additional 65 million yuan for 2025 [2] Market Environment - From 2023 onwards, tightening fiscal spending at various levels has significantly reduced the budget of the core customer, the public security system, leading to a decline in demand for testing equipment and services [3] - The amount won in bids dropped from 110.2131 million yuan in 2022 to 68.1250 million yuan in 2023, a decrease of 38.19%, resulting in a substantial decline in revenue and profit [3] - Actual revenue from 2023 to 2025 is projected to be only 42.25% to 50.35% of the forecasted values, with net profit realization rates between -2.39% and 20.66% [3] Goodwill Impairment Risk - Guofa has issued a clear warning regarding the risk of goodwill impairment, emphasizing that the realization of goodwill from the acquisition of Gaosheng is highly dependent on its future profitability [4] - Factors such as technological iteration, intensified competition, policy adjustments, or subpar market promotion could trigger immediate goodwill impairment [4] - The company highlighted that even minor declines in revenue and gross margin could lead to disproportionately large impairment losses, significantly amplifying overall performance volatility and potentially resulting in a shift from profit to loss [4]